Guides et références
Update on herpes zoster vaccination: A family practitioner's guide
The objective of this Update is to answer frequently asked questions surrounding the use of the herpes zoster (shingles) vaccine.
Advice for consideration of quadrivalent (A, C, Y, W135) meningococcal conjugate vaccine
Contains information about the epidemiology of meningococcal disease and the recommended use of vaccines to protect against infection.
Conseil pour considération du vaccin conjugué quadrivalent contre le méningocoque
Contient de l’information au sujet de l’épidémiologie de la maladie à méningocoque et l’utilisation recommandée des vaccins visant à protéger contre l’infection.
Déclaration sur l'utilisation recommandée du vaccin contre le virus de l'herpès zoster
La présente déclaration fournit des recommandations pour l’utilisation de ZostavaxMC chez les adultes canadiens. À mesure que de nouveaux renseignements concernant ZostavaxMC et le fardeau de la maladie seront accessibles, ces recommandations seront révisées. Les questions relatives à la rentabilité, à l’acceptabilité et à la faisabilité des programmes de vaccination seront étudiées par d’autres groupes provinciaux ou fédéraux.
Helping healthcare workers decide : evaluation of an influenza immunization decision tool
Despite free and easy access to influenza vaccine, and resource consuming campaigns, immunization rates among health care workers (HCW) remain unacceptably low. This is in part due to decisional conflict, which may be alleviated by a decision aid. To address this issue we developed the Ottawa Influenza Decision Aid (OIDA) to help HCW make an informed decision about influenza immunization. Results of this study support the OIDA as a useful tool for HCWs considering influenza immunization.
Literature review on one-dose and two-dose varicella vaccination
In 2006, the Advisory Committee on Immunization Practices (ACIP) approved a routine 2-dose varicella vaccination schedule for children. The purpose of this document is to review information on the epidemiology of varicella, compare the effectiveness of one dose of varicella vaccine with two doses, and to consider a potential change to the current National Advisory Committee on Immunization (NACI) recommendation for a one-dose childhood varicella vaccination program.
Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline
Injections for vaccinations, the most common source of iatrogenic pain in childhood, are administered repeatedly to almost all Canadian children throughout infancy, childhood and adolescence. The pain associated with such injections is a source of distress for children, their parents and those administering the injections. . . . Minimizing pain during childhood vaccination can help to prevent distress, development of needle fears and subsequent health care avoidance behaviours. . . . Our objective was to develop a clinical practice guideline . . . to assist clinicians in managing procedure-related pain and distress among children undergoing vaccine injections.
Revue de la littérature sur la vaccination contre la varicelle à l'aide d'une ou de deux doses
En 2006, l’Advisory Committee on Immunization Practices (ACIP) des États-Unis a approuvé un calendrier d’immunisation systématique des enfants contre la varicelle prévoyant l’administration de deux doses. L’objet du présent rapport est d’examiner l’information dont on dispose sur l’épidémiologie de la varicelle, de déterminer si l’administration de deux doses du vaccin antivaricelleux est plus efficace qu’une seule dose et d’étudier la possibilité de modifier la recommandation du Comité consultatif national de l’immunisation (CCNI), qui préconise actuellement l’administration d’une seule dose du vaccin chez les enfants.
Setting the stage for advancements in immunization in Canada : summary report
The Canadian Public Health Association’s Invitational Roundtable Series: Setting the Stage for Advancements in Immunization in Canada took place in Ottawa on October 5, 2009. Key stakeholders from government, industry and the public health sector came together to discuss Canada’s current immunization environment, explore Canada’s readiness for new developments in immunization, and optimize the health benefits to all Canadians that will arise from further vaccine developments.
Statement on the recommended use of Herpes zoster vaccine
This statement provides recommendations for use of Zostavax in Canadian adults. As new information regarding Zostavax and/or the burden of illness becomes available, the recommendations will be reviewed. Issues including cost-effectiveness, acceptability of vaccine programs, and feasibility will be addressed by other provincial or federal groups.